Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023 15:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023 06:45 ET
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 23, 2023 16:30 ET
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Long-Acting Drug Delivery Technologies and Services Global Market Report 2023: Continued Shift from Conventional Drug Delivery Strategies Boosts Growth
January 31, 2023 07:58 ET
|
Research and Markets
Dublin, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The "Long-Acting Drug Delivery Technologies and Services Market - Distribution by Principle, Strategy, Compatible Dosage Form, Type of Molecule Delivered,...
Non-Viral / Intracellular Drug Delivery Systems Global Market Report 2022: Demand for Systems That Can Efficiently Deliver Therapeutic Interventions in Intracellular Spaces Bolsters Growth
January 13, 2023 07:28 ET
|
Research and Markets
Dublin, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The "Non-Viral / Intracellular Drug Delivery Systems Market by Type of Molecule, Type of Biologics Delivered, Type of Vehicle Used, Type of Therapeutic...
Global Controlled Release Drug Delivery Market Analysis Report 2022-2028: Comprehensive Clinical insight on 200+ Drugs in Clinical Trials and 150+ Drug Available in the Market
January 09, 2023 07:33 ET
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028" clinical trials has been added to ...
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 04, 2023 06:45 ET
|
Cingulate Inc.
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04,...
Geocann and Sunderstorm expand KANHA brand internationally, becoming the first North American cannabis edibles brand to launch in Asia
December 08, 2022 12:45 ET
|
Geocann
FORT COLLINS, Colo., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Geocann and Sunderstorm are proud to announce the expansion of their partnership to key international markets that will begin with Thailand....
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
December 01, 2022 14:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
November 30, 2022 15:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...